Cell Therapy Catapult appoints Chairman

The Technology Strategy Board has announced the appointment of Dr John Brown CBE, FRSE as Chairman of the Cell Therapy Catapult a new centre that will help to grow a viable and sustainable cell therapy industry in the UK. With access to finance, clinical and technical expertise to allow the rapid exploitation of cell therapies, the Catapult will enable the UK to be a global leader in the development and commercial exploitation of cell therapies and encourage inward investment to support the growth of the commercial sector. It will also work with UK companies to help turn innovations in cell therapies into commercial products capable of transforming the lives of people with serious or chronic illnesses.

Dr Brown brings with him over 30 years experience in the pharmaceutical and biotechnology sector. During his career Dr Brown has held a variety of positions that will be relevant to the Catapult including CEO and Finance Director of UK vaccine company Acambis plc, Chairman of medical diagnostics company Axis-Shield plc and Chairman of specialist healthcare company, BTG plc.

Minister for Universities and Science David Willetts said:"Innovation and technology are an important part of our emerging industrial strategy, and the Catapult programme is central to making sure we are delivering the long term support and development that sectors like Cell Therapy require.

“This is an exciting time for the Cell Therapy Catapult, as it is only weeks away from opening its doors. John Brown has a wealth of experience in running businesses in the life sciences sector, and the skills he can bring to the table are exactly what we need to help get this latest Catapult off the ground."